UNSPSC 51361701: Butoctamide

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6MDC25LQSR. European Medicines Agency schedules Butoctamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06028MIG. Butoctamide generally arises in the molecular formula C12H25NO2.

UNSPSC 51361701 Butoctamide is a Commodity code that in recent state and local procurement activity encompasses a broader range of pharmaceutical products and drug-related systems than the code name alone suggests. The three most recent opportunities solicited under this code show state and local governments buying naloxone and drug deactivation systems for emergency response and community health, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements, and exploring direct-to-manufacturer prescription fulfillment capabilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, with Oregon participation). The mix reflects both standalone county procurement and coordinated purchasing vehicles that serve multiple jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota, with interstate reach through the MMCAP cooperative. Recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (due July 26, 2023); the Texas HHS Commission's RFI regarding direct-to-manufacturer prescription programs (response deadline April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Seminole County solicitation requires shipping and delivery inclusion, E-Verify compliance, and workers' compensation and liability insurance. The MMCAP RFP mandates distribution through three authorized wholesalers, current Good Manufacturing Practices and Drug Supply Chain Security Act compliance, $5 million commercial general liability coverage, and pricing submission in CSV format, with evaluation weighted 75 percent on price competitiveness and 25 percent across administrative compliance, EDI capability, and fee structure. No source material identifies set-aside designations under this code.